Becton, Dickinson and Company (NYSE:BDX) Given Consensus Recommendation of “Hold” by Analysts

Becton, Dickinson and Company (NYSE:BDXGet Rating) has received a consensus rating of “Hold” from the ten analysts that are currently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $275.63.

Several brokerages have recently issued reports on BDX. Wells Fargo & Company upped their price target on shares of Becton, Dickinson and from $275.00 to $285.00 and gave the stock an “equal weight” rating in a report on Friday, April 1st. Piper Sandler decreased their price objective on Becton, Dickinson and from $265.00 to $255.00 in a report on Thursday. Argus increased their price objective on Becton, Dickinson and from $275.00 to $310.00 in a report on Monday, February 28th. Bank of America assumed coverage on Becton, Dickinson and in a report on Tuesday, March 1st. They issued a “neutral” rating for the company. Finally, SVB Leerink increased their price objective on Becton, Dickinson and from $270.00 to $275.00 and gave the company a “market perform” rating in a report on Friday, February 4th.

Shares of NYSE:BDX opened at $257.97 on Monday. The company has a fifty day moving average of $263.40 and a 200-day moving average of $257.30. The company has a market capitalization of $73.46 billion, a PE ratio of 40.69, a price-to-earnings-growth ratio of 3.21 and a beta of 0.64. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.78 and a current ratio of 1.53. Becton, Dickinson and has a 52-week low of $235.13 and a 52-week high of $280.62.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The medical instruments supplier reported $3.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.99 by $0.19. The company had revenue of $5.01 billion during the quarter, compared to the consensus estimate of $4.78 billion. Becton, Dickinson and had a net margin of 9.59% and a return on equity of 14.91%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the prior year, the business earned $3.19 earnings per share. On average, equities analysts forecast that Becton, Dickinson and will post 12.74 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 30th. Shareholders of record on Thursday, June 9th will be given a dividend of $0.87 per share. This represents a $3.48 dividend on an annualized basis and a yield of 1.35%. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 54.89%.

In other news, Director Claire Fraser sold 841 shares of the stock in a transaction dated Tuesday, February 8th. The shares were sold at an average price of $271.70, for a total transaction of $228,499.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Betty D. Larson sold 14,374 shares of Becton, Dickinson and stock in a transaction on Friday, February 25th. The stock was sold at an average price of $271.90, for a total transaction of $3,908,290.60. The disclosure for this sale can be found here. Corporate insiders own 0.50% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in BDX. Retirement Planning Co of New England Inc. boosted its stake in Becton, Dickinson and by 12.4% during the first quarter. Retirement Planning Co of New England Inc. now owns 1,366 shares of the medical instruments supplier’s stock worth $363,000 after acquiring an additional 151 shares in the last quarter. Great Lakes Advisors LLC lifted its holdings in Becton, Dickinson and by 4.3% during the first quarter. Great Lakes Advisors LLC now owns 12,233 shares of the medical instruments supplier’s stock valued at $3,254,000 after purchasing an additional 505 shares in the last quarter. Jacobi Capital Management LLC increased its stake in shares of Becton, Dickinson and by 4.5% in the first quarter. Jacobi Capital Management LLC now owns 3,577 shares of the medical instruments supplier’s stock worth $951,000 after purchasing an additional 153 shares in the last quarter. Los Angeles Capital Management LLC increased its stake in shares of Becton, Dickinson and by 445.3% in the first quarter. Los Angeles Capital Management LLC now owns 13,109 shares of the medical instruments supplier’s stock worth $3,487,000 after purchasing an additional 10,705 shares in the last quarter. Finally, Mawer Investment Management Ltd. increased its stake in shares of Becton, Dickinson and by 4.2% in the first quarter. Mawer Investment Management Ltd. now owns 749,859 shares of the medical instruments supplier’s stock worth $194,464,000 after purchasing an additional 30,103 shares in the last quarter. Hedge funds and other institutional investors own 86.58% of the company’s stock.

About Becton, Dickinson and (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Further Reading

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.